Investigational Drug Information for Preladenant
✉ Email this page to a colleague
What is the development status for investigational drug Preladenant?
Preladenant is an investigational drug.
There have been 13 clinical trials for Preladenant.
The most recent clinical trial was a Phase 3 trial, which was initiated on November 19th 2010.
The most common disease conditions in clinical trials are Parkinson Disease, Movement Disorders, and Dyskinesias. The leading clinical trial sponsors are Merck Sharp & Dohme Corp., Oregon Health and Science University, and [disabled in preview].
Summary for Preladenant
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 247 |
| WIPO Patent Applications | 205 |
| Japanese Patent Applications | 47 |
| Clinical Trial Progress | Phase 3 (2010-11-19) |
| Vendors | 59 |
Recent Clinical Trials for Preladenant
| Title | Sponsor | Phase |
|---|---|---|
| Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062) | Merck Sharp & Dohme Corp. | Phase 1 |
| A Study to Assess Pharmacokinetics of Preladenant in Participants With Chronic Hepatic Impairment (P06513) | Merck Sharp & Dohme Corp. | Phase 1 |
| A Study to Assess Pharmacokinetics (PK) of Preladenant in Participants With Chronic Renal Impairment (CRI) (P06512) | Merck Sharp & Dohme Corp. | Phase 1 |
Clinical Trial Summary for Preladenant
Top disease conditions for Preladenant
Top clinical trial sponsors for Preladenant
US Patents for Preladenant
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
